Each passing day, the digital and physical are becoming intertwined. As such, we are focused on building one of the core missing elements in the frontier of technology: the bridge of emotions. Our team is looking to lead the next singularity point of the digital age by translating human emotions to binary, and rendering mental states into observable information.
Striving to connect that which is uniquely human with ingenious hi-tech, each TEM product is meant to improve the quality of life through innovative technology aimed at our emotional, mental and human needs. We use the virtual world as basis for improving the quality of life for us, the inhabitants of the real world.
BreezoMeter is a big-data-driven company that offers real-time, location-based outdoor air quality data via API for businesses and municipalities. Our mission is to help cities and businesses improve the health and quality of life for millions of people worldwide, by providing the most accurate air quality data in a format as simple, intuitive, and actionable as weather data.
Using multiple data layers including governmental monitoring stations, air dispersion models, satellite data, weather data and traffic conditions, combined with computational models, machine learning and proprietary spatial interpolation algorithms, BreezoMeter shows with high accuracy what is in the air you breathe, and can provide actionable health recommendations per population segment. Armed with this information, businesses can help their customers reduce exposure to harmful air pollutants. Today, millions of people make informed decisions on well-being using our air quality data and our company services. We aim to reach more than 6 billion people (85% of the world’s population) who live in areas where WHO air quality guidelines are exceeded.
BioGenCell is a clinical stage, biotechnology startup company, developing a disruptive biotechnology platform that combines the power of immunology and stem cell therapies to transform patient's blood into a lifesaving cellular treatment.
Our technology enables a long lasting, safe, effective, and accessible cellular therapy for the treatment of various vascular diseases which are the #1 death and disability cause in the world.
Our leading product BCG101, is designed to treat CLI (Critical Limb Ischemia), a chronic condition typical of diabetic and smoking populations, leading to amputation and death.
We have conducted FIH (First In Human) clinical trials with very promising results. Patients experience wound healing, walking ability improvement, reduction of pain and a major improvement in their quality of life a year after the treatment.